Five Prime Therapeutics Inc. (NASDAQ:FPRX)’s share price was up 5.3% during trading on Monday . The stock traded as high as $48.69 and last traded at $47.97, with a volume of 515,791 shares trading hands. The stock had previously closed at $45.55.

Several equities analysts recently commented on FPRX shares. Leerink Swann reissued an “outperform” rating and issued a $58.00 price objective (up previously from $45.00) on shares of Five Prime Therapeutics in a research note on Monday, August 8th. Jefferies Group reaffirmed a “buy” rating on shares of Five Prime Therapeutics in a research note on Sunday, May 8th. Credit Suisse Group AG reaffirmed a “buy” rating on shares of Five Prime Therapeutics in a research note on Wednesday, June 8th. Finally, Oppenheimer Holdings Inc. reaffirmed an “outperform” rating and set a $48.00 price target on shares of Five Prime Therapeutics in a research note on Thursday, May 19th. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Five Prime Therapeutics has an average rating of “Buy” and an average target price of $52.33.

The firm has a 50 day moving average of $47.00 and a 200-day moving average of $41.80. The stock has a market capitalization of $1.32 billion and a P/E ratio of 5.50.

Five Prime Therapeutics (NASDAQ:FPRX) last released its earnings results on Thursday, August 4th. The company reported ($0.49) earnings per share for the quarter, topping the consensus estimate of ($0.56) by $0.07. The business had revenue of $9.23 million for the quarter, compared to the consensus estimate of $6.38 million. The firm’s revenue for the quarter was up 46.1% compared to the same quarter last year. During the same quarter last year, the business posted ($0.45) earnings per share. On average, equities analysts anticipate that Five Prime Therapeutics Inc. will post ($2.37) EPS for the current year.

In other news, Director William R. Ringo sold 500 shares of Five Prime Therapeutics stock in a transaction on Monday, August 1st. The stock was sold at an average price of $50.77, for a total transaction of $25,385.00. Following the completion of the sale, the director now directly owns 500 shares in the company, valued at $25,385. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Peder Jensen sold 12,195 shares of Five Prime Therapeutics stock in a transaction on Wednesday, July 27th. The stock was sold at an average price of $49.50, for a total value of $603,652.50. Following the sale, the director now owns 12,195 shares of the company’s stock, valued at $603,652.50. The disclosure for this sale can be found here.

An institutional investor recently bought a new position in Five Prime Therapeutics stock. RS Investment Management Co. LLC acquired a new stake in shares of Five Prime Therapeutics Inc. (NASDAQ:FPRX) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 511,170 shares of the company’s stock, valued at approximately $21,214,000. RS Investment Management Co. LLC owned approximately 1.86% of Five Prime Therapeutics as of its most recent filing with the SEC.

Five Prime Therapeutics, Inc (Five Prime) is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company has three product candidates in clinical development covering multiple potential indications. It focuses on immuno-oncology, an area in which it has clinical and discovery programs, and product and discovery collaborations.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.